Comparative effectiveness of sodiumglucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis

BMJ Open

Volumn 6, Issue 1, 2016, Pages

  Chen, Min ^a   Xie, Chun Guang ^a   Gao, Hong ^a   Zheng, Hui ^a   Chen, Qin ^b   Fang, Jian Qiao ^b  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER;

CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; HUMAN; HYPERGLYCEMIA; KETOACIDOSIS; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADULT; AGED; BODY WEIGHT; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 84960439287     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010252     Document Type: Review

References (40)

1. Cheng YJ, Imperatore G, Geiss LS, et al. Secular changes in the age-specific prevalence of diabetes among U.S. adults: 1988-2010. Diabetes Care 2013;36:2690-6.
2. Cheng YJ, Gregg EW, Geiss LS, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009;32:2027-32.
3. Di Angelantonio E, Gao P, Khan H, et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 2014;311:1225-33.
4. Matsushita K, Blecker S, Pazin-Filho A, et al. The association of hemoglobin A1C with incident heart failure among people without diabetes: The atherosclerosis risk in communities study. Diabetes 2010;59:2020-6.
5. Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: Implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145-50.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
8. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.
10. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetesa systematic review and meta-analysis. Ann Intern Med 2013;159:262-74.
11. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2014;16:984-93.
12. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis. Diabetes Obes Metab 2014;16:433-42.
13. Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLoS ONE 2015;10:e0125879.
14. Mearns ES, Saulsberry WJ, White CM, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: A network meta-analysis. Diabet Med 2015;32:1530-40.
15. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:457-66.
16. Yang T, Lu M, Ma L, et al. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: A meta-analysis. Eur J Clin Pharmacol 2015;71:1325-32.
17. Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:e001007.
18. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8.
19. Kashiwagi A, Kazuta K, Yoshida S, et al. Randomized, placebocontrolled, double-blind glycemic control trial of novel sodiumdependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2014;5:382-91.
20. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65.
21. Seino Y, Inagaki N, Haneda M, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2015;6:443-53.
22. Storgaard H, Gluud LL, Christensen M, et al. The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: Protocol for a systematic review with meta-analysis of randomised trials. BMJ Open 2014;4:e005378.
23. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7.
24. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24.
25. Rucker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24.
26. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-6.
27. Cherney D, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28.
28. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl 1):S81-90.
29. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 2015;54:691-708.
30. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
31. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-93.
32. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52.
33. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502.
34. Kovacs C, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-58.
35. Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 2014;16:628-35.
36. Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I2 in assessing heterogeneity may mislead. BMC Med Res Methodol 2008;8:79.
37. St Jeor ST, Brunner RL, Harrington ME, et al. A classification system to evaluate weight maintainers, gainers, and losers. J Am Diet Assoc 1997;97:481-8.
38. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: A meta-analysis in 73,913 patients. J Hypertens 2011;29:1253-69.
39. Krahn U, Binder H, Konig J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 2013;13:35.
40. Higgins JP, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110.